Raymond James Trust N.A. Buys 1,565 Shares of Edwards Lifesciences Co. (NYSE:EW)

Raymond James Trust N.A. increased its stake in shares of Edwards Lifesciences Co. (NYSE:EWGet Rating) by 3.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 42,988 shares of the medical research company’s stock after purchasing an additional 1,565 shares during the quarter. Raymond James Trust N.A.’s holdings in Edwards Lifesciences were worth $4,088,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. American National Bank grew its position in Edwards Lifesciences by 99.1% in the 1st quarter. American National Bank now owns 233 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 116 shares during the last quarter. Core Alternative Capital lifted its stake in shares of Edwards Lifesciences by 513.2% during the 1st quarter. Core Alternative Capital now owns 233 shares of the medical research company’s stock worth $27,000 after purchasing an additional 195 shares during the last quarter. Rinkey Investments purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth $29,000. JJJ Advisors Inc. lifted its stake in shares of Edwards Lifesciences by 79.1% during the 1st quarter. JJJ Advisors Inc. now owns 283 shares of the medical research company’s stock worth $33,000 after purchasing an additional 125 shares during the last quarter. Finally, Gemmer Asset Management LLC purchased a new stake in shares of Edwards Lifesciences during the 1st quarter worth $36,000. Institutional investors own 81.33% of the company’s stock.

Insider Buying and Selling

In related news, CEO Michael A. Mussallem sold 19,875 shares of the company’s stock in a transaction that occurred on Thursday, July 14th. The stock was sold at an average price of $95.88, for a total value of $1,905,615.00. Following the sale, the chief executive officer now owns 166,853 shares in the company, valued at approximately $15,997,865.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Edwards Lifesciences news, VP Larry L. Wood sold 7,242 shares of the stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $95.90, for a total transaction of $694,507.80. Following the sale, the vice president now owns 202,232 shares in the company, valued at approximately $19,394,048.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Michael A. Mussallem sold 19,875 shares of the stock in a transaction on Thursday, July 14th. The stock was sold at an average price of $95.88, for a total value of $1,905,615.00. Following the transaction, the chief executive officer now directly owns 166,853 shares in the company, valued at approximately $15,997,865.64. The disclosure for this sale can be found here. Insiders have sold a total of 86,128 shares of company stock worth $8,223,839 in the last quarter. Company insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on EW. Morgan Stanley decreased their price target on Edwards Lifesciences from $136.00 to $119.00 and set an “overweight” rating for the company in a research note on Friday, July 15th. Canaccord Genuity Group lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $115.00 to $106.00 in a report on Friday, July 29th. Stifel Nicolaus dropped their target price on Edwards Lifesciences from $128.00 to $115.00 in a report on Monday, July 18th. Cowen dropped their target price on Edwards Lifesciences from $140.00 to $125.00 in a report on Monday, July 11th. Finally, StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Wednesday, August 17th. Three analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $125.81.

Edwards Lifesciences Stock Performance

NYSE EW opened at $84.17 on Friday. The company has a current ratio of 3.37, a quick ratio of 2.60 and a debt-to-equity ratio of 0.10. The business’s 50 day moving average is $97.39 and its two-hundred day moving average is $101.83. Edwards Lifesciences Co. has a 12-month low of $83.42 and a 12-month high of $131.73. The stock has a market capitalization of $52.18 billion, a price-to-earnings ratio of 36.44, a PEG ratio of 2.52 and a beta of 1.14.

Edwards Lifesciences (NYSE:EWGet Rating) last released its quarterly earnings results on Thursday, July 28th. The medical research company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.01). The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 24.77% and a net margin of 27.18%. The business’s revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 EPS. Research analysts expect that Edwards Lifesciences Co. will post 2.51 EPS for the current year.

About Edwards Lifesciences

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Featured Articles

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.